Patents by Inventor Eva Marie W. LINDHOLM

Eva Marie W. LINDHOLM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1
    Publication number: 20210095277
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to SREBF1 pre-mRNA intron and exon sequences, which are capable of inhibiting the expression of SREBP1 protein. Inhibition of SREBF1 expression is beneficial for a range of medical disorders including cardiovascular disease, type 2 diabetes, fatty liver, metabolic diseases, and cancer.
    Type: Application
    Filed: January 16, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Eva Marie W. LINDHOLM, Steffen SCHMIDT
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION
    Publication number: 20200216845
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of RelA in a target cell. The oligonucleotides are complementary to mammalian RELA pre-m RNA intron sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.
    Type: Application
    Filed: January 10, 2018
    Publication date: July 9, 2020
    Inventors: Eva Marie W. LINDHOLM, Lykke PEDERSEN, Steffen SCHMIDT
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION
    Publication number: 20190367920
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of NF-?B1 in a target cell. The oligonucleotides are complementary to mammalian NFKB1 pre-mRNA intron sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.
    Type: Application
    Filed: January 10, 2018
    Publication date: December 5, 2019
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Eva Marie W. LINDHOLM, Lykke PEDERSEN, Steffen SCHMIDT
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB2 EXPRESSION
    Publication number: 20190345495
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of NF-kB2 in a target cell. The oligonucleotides are complementary to mammalian NFKB2 pre-mRNA sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 14, 2019
    Inventors: Eva Marie W. LINDHOLM, Lykke PEDERSEN, Steffen SCHMIDT
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELB EXPRESSION
    Publication number: 20190345496
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of RelB in a target cell. The oligonucleotides are complementary to mammalian RELB pre-mRNA sequence. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 14, 2019
    Inventors: Eva Marie W. LINDHOLM, Lykke PEDERSEN, Steffen SCHMIDT
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING REL EXPRESSION
    Publication number: 20190338286
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of c-Rel in a target cell. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancer, inflammation or autoimmune diseases using the oligonucleotide.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 7, 2019
    Inventors: Eva Marie W. LINDHOLM, Lykke PEDERSEN, Steffen SCHMIDT